Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.73 |
| ▸ | MAOA | P21397 | 12/20 | 0.55 |
| ▸ | MAOB | P27338 | 12/20 | 0.55 |
| ▸ | PRKCI | P41743 | 1/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | CDC25B | P30305 | 1/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25945154 | 0.98 | MEN1 (0.70) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL4878423 | 0.95 | MEN1 (0.67) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL179913 | 0.93 | MEN1 (0.64) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL8284440 | 0.92 | MEN1 (0.69) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL11111147 | 0.88 | MEN1 (0.59) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL15549968 | 0.85 | MEN1 (1.00) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL20681358 | 0.84 | MEN1 (0.54) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL8615975 | 0.79 | MEN1 (0.55) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL8639793 | 0.79 | MAOA (0.55) | MEN1MAPK1KMT2ANPSR1MAOA | |
| SCHEMBL423181 | 0.79 | MAOA (0.60) | MEN1MAPK1KMT2ANPSR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-7858824-B2 | Aralkyltetrahydropyridines, their preparation and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-7858824-B2 | Aralkyltetrahydropyridines, their preparation and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-7858824-B2 | Aralkyltetrahydropyridines, their preparation and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | ABBVIE INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080097117-A1 | Aralkyltetrahydropyridines, Their Preparation and Pharmaceutical Compositions Containing Them | SANOFI-AVENTIS (FR) | 2008-04-24 | — | — | US | disclosed |
| US-20080097117-A1 | Aralkyltetrahydropyridines, Their Preparation and Pharmaceutical Compositions Containing Them | SANOFI-AVENTIS (FR) | 2008-04-24 | — | — | US | disclosed |
| US-20080097117-A1 | Aralkyltetrahydropyridines, Their Preparation and Pharmaceutical Compositions Containing Them | SANOFI-AVENTIS (FR) | 2008-04-24 | — | — | US | disclosed |
| US-7326723-B2 | Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-02-05 | — | — | US | disclosed |
| US-7326723-B2 | Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-02-05 | — | — | US | disclosed |
| US-7326723-B2 | Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-02-05 | — | — | US | disclosed |
| EP-1438291-B1 | ARALKYL-TETRAHYDRO-PYRIDINES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI AVENTIS (FR) | 2005-09-07 | — | — | EP | disclosed |
| US-20050014795-A1 | Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same | SANOFI-SYNTHELABO (FR) | 2005-01-20 | — | — | US | disclosed |
| EP-0769015-B1 | PHOSPHONIC ACID COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-03-14 | — | — | EP | disclosed |
| EP-0769015-A1 | PHOSPHONIC ACID COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1997-04-23 | — | — | EP | disclosed |
| WO-1996001267-A1 | PHOSPHONIC ACID COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | DPYD, TYMS, UMPS | MEN1 2195/4885MAPK1 3023/4885KMT2A 2423/4885 |
| US-20050014795-A1 | Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same | CYCS, NADK, CYP2F1 | MEN1 2011/4885MAPK1 2002/4885KMT2A 4713/4885 |
| US-20080097117-A1 | Aralkyltetrahydropyridines, Their Preparation and Pharmaceutical Compositions Containing Them | CYP3A43, CYCS, CCNY | MEN1 3562/4885MAPK1 2817/4885KMT2A 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.